Post-marketing surveillance on treatment of 5,665 patients with atopic dermatitis using the calcineurin inhibitor pimecrolimus: Positive effects on major symptoms of atopic dermatitis and on quality of life;Beobachtungsstudie zur behandlung der atopischen dermatitis mit dem calcineurininhibitor pimecrolimus an 5665 patienten: Positive wirkung auf leitsymptome der atopischen dermatitis und auf die lebensqualität

JDDG - Journal of the German Society of Dermatology

Volumn 4, Issue 4, 2006, Pages 301-306

  Sunderkötter, Cord ^a,b   Weiss, Johannes M ^a   Bextermöller, Raphael ^c   Löffler, Helena ^c   Schneider, Dirk ^d  

^a UNIVERSITY OF ULM   (Germany)

^b UNIVERSITY OF MÜNSTER   (Germany)

^c Novartis Pharma GmbH   (Germany)

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Atopic dermatitis; Pimecrolimus; Post marketing surveillance; Pruritus; Quality of life

Indexed keywords

CALCINEURIN INHIBITOR; PIMECROLIMUS; CALCINEURIN; DERMATOLOGICAL AGENT; DRUG DERIVATIVE; TACROLIMUS;

ADOLESCENT; ADULT; APPLICATION SITE BURNING; APPLICATION SITE ERYTHEMA; APPLICATION SITE PRURITUS; ARTICLE; ATOPIC DERMATITIS; CHILD; COHORT ANALYSIS; DRUG EFFICACY; DRUG TOLERABILITY; ERYTHEMA; FEMALE; HUMAN; LICHENOID ERUPTION; MAJOR CLINICAL STUDY; MALE; OUTPATIENT DEPARTMENT; PHYSICIAN; POSTMARKETING SURVEILLANCE; PRURITUS; QUALITY OF LIFE; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; SYMPTOMATOLOGY; TREATMENT DURATION; CLINICAL TRIAL; DRUG ANTAGONISM; GERMANY; INFANT; METHODOLOGY; NEWBORN; PRESCHOOL CHILD; PREVALENCE; PROGNOSIS; TREATMENT OUTCOME;

ADOLESCENT; CALCINEURIN; CHILD; CHILD, PRESCHOOL; DERMATITIS, ATOPIC; DERMATOLOGIC AGENTS; FEMALE; GERMANY; HUMANS; INFANT; INFANT, NEWBORN; MALE; PREVALENCE; PRODUCT SURVEILLANCE, POSTMARKETING; PROGNOSIS; QUALITY OF LIFE; TACROLIMUS; TREATMENT OUTCOME;

EID: 33646838586     PISSN: 16100379     EISSN: 16100387     Source Type: Journal    
DOI: 10.1111/j.1610-0387.2006.05932.x     Document Type: Article

References (23)

1. Schultz LF. The epidemiology of atopic dermatitis. Monogr Allergy 1993; 31: 9-28.
2. Kay J., Gawkrodger DJ, Mortimer MJ, Jaron AG. The prevalence of childhood atopic eczema in a general population. J. Am. Acad. Dermatol 1994; 30: 35-39.
3. Williams HC, Wuthrich B. The natural history of atopic dermatitis. In: Williams HC. Atopic dermatitis: the epidemiology, causes and prevention of atopic eczema. Cambridge: Cambridge University Press, 2000: 41-59.
4. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) - a simple practical measure for routine clinical use. Clin. Exp. Dermatol. 1994; 19: 210-216.
5. Morgan M, McCreedy R, Simpson J, Hay RJ. Dermatology quality of life scales - a measure of the impact of skin diseases. Br J Dermatol 1997; 136: 202-206.
6. Lewis-Jones MS, Finlay AY. The Children's Dermatology Life Quality Index (CDLQI): initial validation and practical use. Br. J. Dermatol. 1995; 132: 942-949.
7. Kiebert G, Sorensen SV, Revicki D, Fagan SC, Doyle JJ, Cohen J, Fivenson D. Atopic dermatitis is associated with a decrement in health-related quality of life. Int. J. Dermatol. 2002; 41: 151-158.
8. Schiffner R, Schiffner-Rohe J, Landthaler M, Stolz W. Treatment of atopic dermatitis and impact on quality of life: a review with emphasis on topical non-corticosteroids. Pharmacoeconomics 2003; 21: 159-179.
9. Pauli-Pott U, Darui A, Beckmann D. Infants with atopic dermatitis: maternal hopelessness, child-rearing attitudes and perceived infant temperament. Psychother. Psychosom 1999; 68: 39-45.
10. Su JC, Kemp AS, Varigos GA, Nolan TM. Atopic eczema: its impact on the family and financial cost. Arch Dis. Child 1997; 76: 159-162.
11. Whalley D, Huels J, McKenna SP, Van Assche D. The benefit of pimecrolimus (Elidel, SDZ ASM 981) on parents' quality of life in the treatment of pediatric atopic dermatitis. Pediatrics 2002; 110: 1133-1136.
12. Grassberger M, Steinhoff M, Schneider D, Luger TA. Pimecrolimus - an anti-inflammatory drug targeting the skin. Exp Dermatol. 2004; 13: 721-730.
13. Alomar A, Berth-Jones J, Bos JD, Giannetti A, Reitamo S, Ruzicka T, Stalder JF, Thestrup-Pedersen K, European Working Group on Atopic Dermatitis. The role of topical calcineurin inhibitors in atopic dermatitis. Br J Dermatol. 2004; 151: 3-27.
14. Meurer M, Fartasch M, Albrecht G, Vogt T, Worm M, Ruzicka T, Altmeyer PJ, Schneider D, Weidinger G, Bräutigam M. Long-term efficacy and safety of Pimecrolimus cream 1 % in adults with moderate atopic dermatitis. Dermatology 2004; 208: 365-372.
15. Kapp A, Papp K, Bingham A, Folster-Holst R, Ortonne JP, Potter PC, Gulliver W, Paul C, Molloy S, Barbier N, Thurston M, de Prost Y. Long-term management of atopic dermatitis in infants with topical pimecrolimus, a nonsteroid anti-inflammatory drug. J. Allergy Clin. Immunol. 2002; 110: 277-284.
16. Eichenfield LF, Beck L. Elidel (pimecrolimus) cream 1 %: a nonsteroidal topical agent for the treatment of atopic dermatitis. J. Allergy Clin. Immunol. 2003; 111: 1153-1168.
17. Mar A, Marks R. The descriptive epidemiology of atopic dermatitis in the community. Australasian Journal of Dematology 1999; 40: 73-78.
18. Williams HC. Epidemiology of atopic dermatitis. Clinical and Experimental Dermatology 2000; 25: 522-529.
19. Kaufmann R, Fölster-Holst R, Höger P, Thaci D, Löffler H, Bräutigam M. Onset of action of pimecrolimus cream 1 % in the treatment of atopic eczema in infants. J Allergy Clin Immunol 2004; 114: 1183-1188.
20. Wahn U, Bos JD, Goodfield M, Caputo R, Papp K, Manjra A, Dobozy A, Paul C, Molloy S, Hultsch T, Graeber M, Cherill R, de Prost Y. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics 2002; 110: e2.
21. Shum KW, Lawton S, Williams HC, Docherty G, Jones J. The British Association of Dermatologists audit of atopic eczema management in secondary care. Phase 3: audit of service outcome. British Journal of Dermatology 200; 142: 721-727.
22. Whalley D, McKenna S, Huels J. Pimecrolimus (SDZ ASM 981) in the treatment of pediatric atopic eczema: benefit to quality of life and health-related quality of life. Annals of Dermatology and Venereology 2002; 129: S426.
23. Meurer M, Folster-Holst R, Wozel G, Weidinger G, Junger M, Brautigam M. Pimecrolimus cream in the long-term management of atopic dermatitis in adults: a six-month study. Dermatology 2002; 205: 271-277.